Kemp Dolliver
Stock Analyst at Brookline Capital
(0.52)
# 3,496
Out of 4,667 analysts
20
Total ratings
30%
Success rate
-27.22%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYEN Eyenovia | Downgrades: Hold | n/a | $0.09 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.89 | - | 2 | Oct 2, 2024 | |
| ONCT Oncternal Therapeutics | Downgrades: Hold | n/a | $1.14 | - | 3 | Sep 12, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $2.19 | +64.38% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $3.18 | +1,032.08% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $5.28 | +494.70% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.37 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $86.45 | +15.67% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.20 | +2,490.91% | 2 | Oct 12, 2023 | |
| PROC Procaps Group | Downgrades: Hold | $4.5 | $0.57 | +687.40% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $2.49 | +904.02% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $9.94 | +88.63% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $1.18 | +577.97% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.60 | +837.76% | 1 | Feb 2, 2022 |
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.09
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.89
Upside: -
Oncternal Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $2.19
Upside: +64.38%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $3.18
Upside: +1,032.08%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $5.28
Upside: +494.70%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.37
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $86.45
Upside: +15.67%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.20
Upside: +2,490.91%
Procaps Group
Sep 6, 2023
Downgrades: Hold
Price Target: $4.5
Current: $0.57
Upside: +687.40%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.49
Upside: +904.02%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $9.94
Upside: +88.63%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $1.18
Upside: +577.97%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.60
Upside: +837.76%